As suggested by Klotz and colleagues [94], targeting of SEMA4D and GPX1 in primary tumors can be a potential therapeutic approach for the abrogating ability of CTCs to colonize the brain and for preventing brain metastasis in BC patients. Here, SEMA4D is linked to breast cancer.